- Home
- SUPN vs ARR Comparison
SUPN vs ARR Comparison
Compare SUPN & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- ARR
- Stock Information
- Founded
- SUPN 2005
- ARR 2008
- Country
- SUPN United States
- ARR United States
- Employees
- SUPN N/A
- ARR N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- ARR Real Estate Investment Trusts
- Sector
- SUPN Health Care
- ARR Real Estate
- Exchange
- SUPN Nasdaq
- ARR Nasdaq
- Market Cap
- SUPN 1.7B
- ARR 1.4B
- IPO Year
- SUPN 2012
- ARR N/A
- Fundamental
- Price
- SUPN $32.90
- ARR $18.34
- Analyst Decision
- SUPN Hold
- ARR Hold
- Analyst Count
- SUPN 2
- ARR 3
- Target Price
- SUPN $36.00
- ARR $21.00
- AVG Volume (30 Days)
- SUPN 787.3K
- ARR 2.9M
- Earning Date
- SUPN 05-07-2025
- ARR 04-24-2025
- Dividend Yield
- SUPN N/A
- ARR 15.85%
- EPS Growth
- SUPN 6500.00
- ARR N/A
- EPS
- SUPN 1.32
- ARR N/A
- Revenue
- SUPN $661,817,000.00
- ARR $39,256,000.00
- Revenue This Year
- SUPN N/A
- ARR $468.02
- Revenue Next Year
- SUPN $8.67
- ARR $45.61
- P/E Ratio
- SUPN $24.90
- ARR N/A
- Revenue Growth
- SUPN 8.94
- ARR N/A
- 52 Week Low
- SUPN $25.53
- ARR $17.35
- 52 Week High
- SUPN $40.28
- ARR $21.93
- Technical
- Relative Strength Index (RSI)
- SUPN 46.17
- ARR 42.85
- Support Level
- SUPN $31.69
- ARR $18.57
- Resistance Level
- SUPN $32.90
- ARR $18.75
- Average True Range (ATR)
- SUPN 0.96
- ARR 0.33
- MACD
- SUPN 0.29
- ARR -0.02
- Stochastic Oscillator
- SUPN 89.25
- ARR 31.63
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.